Analysis of Neoadjuvant Chemotherapy Utilization, Pathologic Response, and Overall Survival in Upper Tract Urothelial Carcinoma
We report significant response rates with NAC and improved OS in patients who experienced pR or pCR. Over a 15-year study period, NAC was underutilized, especially in nonacademic settings and among patients living farther from care facilities, underscoring the need for improved regionalization and multidisciplinary approaches in UTUC management.
Authors
- Ryan Michael Antar (ORCID: https://orcid.org/0000-0003-0947-407X)
- Matthew Klein
- Vincent Xu (ORCID: https://orcid.org/0000-0002-4562-4824)
- Michael J. Whalen (ORCID: https://orcid.org/0000-0002-2423-072X)
- Oluwafolajimi Adesanya (ORCID: https://orcid.org/0000-0002-8716-7457)
- Phat Chang
- Sarah Azari (ORCID: https://orcid.org/0000-0001-7194-7873)
- Arthur Drouaud (ORCID: https://orcid.org/0000-0002-2240-6875)
- Armine K. Smith (ORCID: https://orcid.org/0000-0002-3846-0235)
- Samita Islam
Institutions
- Johns Hopkins University (US)
- University of Illinois Urbana-Champaign (US)
- George Washington University (US)
- Johns Hopkins Medicine (US)
- Drexel University (US)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1016/j.clgc.2024.102224
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.72